Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

  • There is currently no data for BMK

Directorate Change

29 Nov 2023 07:01

RNS Number : 9803U
Benchmark Holdings PLC
29 November 2023
 

29 November 2023

 

Benchmark Holdings plc

("Benchmark" or the "Company")

Directorate Change

The Company is pleased to announce the appointment of Jonathan Esfandi as Non-Executive Director. Mr Esfandi is the founder and managing partner at JNE Partners LLP. 

Mr. Esfandi will act as shareholder representative of JNE Partners LLP, a significant shareholder of the Company, and therefore the Board has concluded that he is not an independent director. 

Laura Lavers, who joined the Board in November 2022, will retire from the Board as a Non-Executive Director with effect from today.

 

Peter George, Chairman, commented:

"We welcome Jonathan to the Board and look forward to working together. On behalf of the Board, I wish to thank Laura Lavers for her contribution over the past year."

The following information is disclosed in accordance with Rule 17 and paragraph (g) of Schedule 2 of the AIM Rules for Companies in connection with the appointment of Jonathan to the Board of the Company:

Full Name: Jonathan Esfandi

Age: 49

Current Directorships: 

JNE PARTNERS LLP

JNE PARTNERS (UK) SERVICES LTD

Former Directorships (previous five years): None within the past five years

Beneficial interest in the equity securities of Benchmark Holdings plc: No direct beneficial interest. Funds managed by JNE Partners LLP have a holding of 169,263,811 shares in Benchmark

There is no further information required to be disclosed under Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.

 

Enquiries

For further information, please contact:

Benchmark Holdings plc

Tel: 0114 240 9939

Trond Williksen, CEO

Septima Maguire, CFO

Ivonne Cantu, Investor Relations

Deutsche Numis (Nominated Adviser and Broker)

Tel: 020 7260 1000

Freddie Barnfield, Duncan Monteith, Sher Shah

MHP

Tel: 020 3128 8004

Katie Hunt, Reg Hoare

benchmark@mhpgroup.com

 

Equity Development

Hannah Crowe

 

Tel: 020 7065 2692

 

About Benchmark

Benchmark is a leading aquaculture biotechnology company. Benchmark's mission is to enable aquaculture producers to improve their sustainability and profitability.

We bring together biology and technology to develop innovative products and solutions which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.

Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), specialist diets and probiotics and sea lice treatments. Find out more at www.benchmarkplc.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOADXBDBXGDDGXI
Date   Source Headline
2nd Jul 20187:00 amRNSAppointment of Executive Director
29th Jun 20187:00 amRNSTotal Voting Rights
27th Jun 20184:36 pmRNSHolding(s) in Company
25th Jun 20184:01 pmRNSHolding(s) in Company
22nd Jun 20184:31 pmRNSHolding(s) in Company
22nd Jun 20187:00 amRNSDIRECTOR DEALINGS
19th Jun 20184:06 pmRNSUpdate on Joint Venture and Placing
19th Jun 20187:00 amRNSInterim Results
8th Jun 20187:00 amRNSJoint Venture, Placing and Trading Update
31st May 20187:00 amRNSTotal Voting Rights
8th May 20187:00 amRNSAppointment of Chairman
30th Apr 201812:23 pmRNSTotal Voting Rights
9th Apr 201811:14 amRNSHolding(s) in Company
5th Apr 20183:58 pmRNSHolding(s) in Company
3rd Apr 20187:00 amRNSTotal Voting Rights
27th Mar 20187:00 amRNSBenchmark hosts Capital Markets Day today
21st Mar 20187:00 amRNSBlock listing six monthly return
8th Mar 20181:37 pmRNSResult of AGM
7th Feb 20189:05 amRNSDirector Dealings
31st Jan 20187:00 amRNSBoard Succession
31st Jan 20187:00 amRNSTotal Voting Rights
25th Jan 201811:54 amRNSDirector Share Options
24th Jan 20183:17 pmRNSHolding(s) in Company
24th Jan 20181:01 pmRNSDirector Dealings
24th Jan 20187:00 amRNSPosting of Annual Report & Notice of AGM
23rd Jan 20187:08 amRNSFinal Results
19th Jan 20184:40 pmRNSSecond Price Monitoring Extn
19th Jan 20184:35 pmRNSPrice Monitoring Extension
5th Jan 20184:19 pmRNSHolding(s) in Company
4th Jan 20184:41 pmRNSSecond Price Monitoring Extn
4th Jan 20184:35 pmRNSPrice Monitoring Extension
12th Dec 20177:00 amRNSCommercial scale field trial of sea lice treatment
7th Dec 20177:00 amRNSBenchmark participates in gene editing research
5th Dec 20177:00 amRNSTrading Update and Notice of Results
8th Nov 20177:00 amRNSDevelopment of disease-resistant shrimp
6th Nov 201712:20 pmRNSReplacement: Directorate Change
6th Nov 20177:00 amRNSDirectorate Change
30th Oct 20177:00 amRNSLand-based Broodstock Facility Reaches Milestone
17th Oct 20177:00 amRNSNew Vaccine Facility Delivers First Production
10th Oct 20172:41 pmRNSHolding(s) in Company
21st Sep 20177:00 amRNSBlock Listing Six Monthly Return
8th Sep 20177:00 amRNSTrading Update
22nd Aug 20177:00 amRNSRenewal of Sales and Marketing Agreement
16th Aug 20177:00 amRNSLaunch of breakthrough purification system
28th Jul 20172:57 pmRNSDirector leave of absence
27th Jun 20177:02 amRNSHalf-year Report
19th Jun 20173:00 pmRNSNotice of Results
25th May 20177:00 amRNSTrading Update and Notice of Results
2nd May 20177:00 amRNSTotal Voting Rights
26th Apr 201710:54 amRNSDirector Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.